• ABOUT US
    • Annovis
      • Executives and Advisors
        • SAB and Board
        • TECHNOLOGIES
          • Pipeline
            • Animal and Human Studies
              • Safety
                • Ongoing Studies
                • NEURODEGENERATION
                  • About Neurodegeneration
                    • Mechanisms of Action
                      • Document Library
                      • NEWS
                        • CONTACT US
                          annovis whute logo.png

                          ANNOVIS BIO
                          1055 Westlakes Drive
                          Suite 300

                          Berwyn, PA 19312

                          ​

                          info@annovisbio.com

                          Website Design by 

                          Lamnia-Logo-White-PNG.png

                          (c) 2019 Annovis Bio, All Rights Reserved 

                           

                          Attacking Alzheimer's Disease and Neurodegeneration by Improving 
                          AXONAL TRANSPORT

                          We enhance the FLOW of Information Along the Information Highway of Nerve Cells

                          ​

                          LEARN MORE ABOUT ANNOVIS
                          NEWS RELEASES

                          July 9, 2019

                          Annovis Appoints Jeffrey McGroarty Chief Financial Officer

                          June 24, 2019

                          QR Pharma Adopts new Corporate Name: Annovis Bio

                          MORE NEWS RELEASES
                          NEUROLOGY NEWS 

                          October 1, 2019
                          Axonal Transport and Neurological Disease

                          May 21, 2019

                          How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?

                          MORE NEUROLOGY NEWS

                          WE ARE DEVELOPING DRUGS FOR ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE, INCLUDING THE ORPHAN INDICATION DEMENTIA AND ALZHEIMER’S IN DOWN SYNDROME

                          ​

                          Our novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population

                          OUR PIPELINE AND PROGRESS

                          5.8M

                          Americans with Alzheimer's Disease

                          increase white.png

                          Increase in Alzheimer diagnoses by 2060

                          3x

                          failure icon.png

                          Failed drug development attempts since 1998

                          130

                          The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that hypothesis looks less credible than ever. 

                          Stat +.png

                          Raymond J. Tesi STAT News April 30, 2019

                          Aducanumab's failure puts pressure on field to look beyond amyloid

                          Ned Pagliarulo March 22, 2019

                          ALZHEIMER'S DISEASE DRUG FAILURE

                          Amyloid Plaque and Aβ is NOT The Only Answer

                          After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

                          Neurotoxic proteins reduce axonal transport and cause a 
                          TOXIC CASCADE 

                          Impaired axonal transport lowers levels of neurotransmitters and neurotrophic proteins leading to nerve cell death.

                          THE EFFECTS OF NEUROTOXIC PROTEINS

                          We Are Working to
                          REVERSE

                          the Toxic Cascade

                          Plaques, tangles, and Lewy bodies represent the end stage of neurodegeneration. The disease STARTS with impaired axonal transport caused by high-levels of neurotoxic proteins.

                          LEARN MORE ABOUT ANVS TECHNOLOGY

                          Attacking Alzheimer's Disease and Neurodegeneration by Improving

                          ​

                          AXONAL TRANSPORT

                          We Enhance the FLOW of Information Along the Information Highway of Nerve Cells

                          ​

                          LEARN MORE ABOUT ANNOVIS
                          ANNOVIS NEWS RELEASES
                          NUEROLOGY NEWS

                          WE ARE DEVELOPING DRUGS FOR ALZHEIMER’S AND PARKINSON’S DISEASE, INCLUDING THE ORPHAN INDICATION DEMENTIA AND ALZHEIMER’S IN DOWN SYNDROME

                          ​

                          Our novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population

                          OUR PIPELINE AND PROGRESS

                          5.8M

                          Americans with Alzheimer's Disease

                          increase white.png

                          Increase in Alzheimer diagnoses by 2060

                          3x

                          failure icon.png

                          Failed drug development attempts since 1998

                          130

                          The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that hypothesis looks less credible than ever. 

                          Stat +.png

                          ALZHEIMER'S DISEASE DRUG FAILURE

                          Amyloid Plaque and Aβ is NOT The Only Answer

                          After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

                          Raymond J. Tesi STAT News April 30, 2019

                          plaque new.jpg

                          Aducanumab's failure puts pressure on field to look beyond amyloid

                          Ned Pagliarulo March 22, 2019

                          Neurotoxic proteins reduce axonal transport and cause a 
                          TOXIC CASCADE 

                          Impaired axonal transport lowers levels of neurotransmitters and neurotrophic proteins leading to nerve cell death.

                          THE EFFECTS OF NEUROTOXIC PROTEINS

                          We Are Working to
                          REVERSE

                          the Toxic Cascade

                          Plaques, tangles, and Lewy bodies represent the end stage of neurodegeneration. The disease STARTS with impaired axonal transport caused by high-levels of neurotoxic proteins.

                          LEARN MORE ABOUT ANVS TECHNOLOGY
                          annovis white black.png
                          • ABOUT US

                          • TECHNOLOGIES

                          • NEURODEGENERATION

                          • NEWS

                          • CONTACT US

                          • Â